A new randomized controlled trial among BRCA1 and BRCA2 carriers comparing neoadjuvant chemotherapy with olaparib versus chemotherapy alone found:

• No improvement in pathologic response (64.1% with olaparib versus 69.8% with chemotherapy alone)
• Yet significant improvement in overall survival (100% at 3 years with olaparib versus 88.2% with chemotherapy alone)
• Superior event-free and breast cancer specific survival

This suggests that adding olaparib may benefit survival for BRCA carriers, even if this is not apparent when looking at pathologic response.

Learn more by reading the full article at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12075821/

Reference: Abraham, et al. Nat Commun. 2025;16(1):4269. PMID: 40360463.